Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL1725528 | 0.91 | MAPT (0.49) | MAPTMEN1KMT2AHPGDSHSPB1 | |
| SCHEMBL6231939 | 0.86 | RAB9A (0.60) | MAPTNPC1RAB9AIDO1ALDH1A1 | |
| SCHEMBL14019155 | 0.86 | KMT2A (0.48) | MAPTMEN1KMT2AHSPB1ALOX12 | |
| SCHEMBL14988369 | 0.83 | NPC1 (0.50) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL6237830 | 0.82 | RAB9A (0.57) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL6239437 | 0.82 | KMT2A (0.53) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14988514 | 0.81 | SCN2A (0.59) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL8702382 | 0.81 | MEN1 (0.56) | MAPTMEN1KMT2AHSPB1NPC1 | |
| SCHEMBL71038 | 0.80 | LMNA (0.54) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL16835955 | 0.80 | MAPT (0.47) | MAPTMEN1KMT2AHSPB1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021121420-A1 | BENZOPYRAZOLE COMPOUND AND INTERMEDIATE, PREPARATION METHOD, AND APPLICATION THEREOF | 江苏凯迪恩医药科技有限公司 | 2021-06-24 | — | — | WO | disclosed |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-9981964-B2 | Maleimide derivatives as modulators of wnt pathway | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-29 | — | — | US | disclosed |
| CN-106061974-B | Maleimide derivatives as the conditioning agent of WNT approach | 新加坡科技研究局 | 2018-04-20 | — | — | CN | disclosed |
| EP-3083622-B1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY SCIENCE TECH & RES (SG) | 2018-03-21 | — | — | EP | disclosed |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-03 | — | — | US | disclosed |
| EP-3083622-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | Agency For Science, Technology And Research (SG) | 2016-10-26 | — | — | EP | disclosed |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2016-03-24 | — | — | US | disclosed |
| US-8546396-B2 | N-(hetero)aryl, 2-(hetero)aryl—substituted acetamides for use as Wnt signaling modulators | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| EP-2623493-A1 | N-(hetero)aryl,2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators | IRM LLC (BM) | 2013-08-07 | — | — | EP | disclosed |
| CN-102731379-A | N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators | IRM LLC | 2012-10-17 | — | — | CN | disclosed |
| CN-102369187-A | N- (hetero) aryl, 2- (hetero) aryl substituted acetamides as WNT signal modulators | IRM LLC | 2012-03-07 | — | — | CN | disclosed |
| EP-2403832-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2012-01-11 | — | — | EP | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | MAPT 4071/4885MEN1 4351/4885KMT2A 1354/4885 |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | WNT1, CTNNB1, CTNNA1 | MAPT 4071/4885MEN1 4351/4885KMT2A 1354/4885 |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | MAPT 4071/4885MEN1 4351/4885KMT2A 1354/4885 |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | WNT1, WNT3, CTNNB1 | MAPT 632/4885MEN1 157/4885KMT2A 3772/4885 |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, WNT3A | MAPT 4134/4885MEN1 4515/4885KMT2A 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.